Drug Profile
MK 8245
Alternative Names: MK-8245Latest Information Update: 17 Jun 2011
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antihyperglycaemics
- Mechanism of Action Stearoyl CoA desaturase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Type 2 diabetes mellitus
Most Recent Events
- 13 Nov 2008 Merck initiates enrolment in a phase I trial for Type-2 diabetes mellitus in USA